Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

e of 20 mg/m2 on days 1 and 2, followed by 36 mg/m2 on days 8, 9 and 15, 16 over a 28-day cycle. The ongoing Phase 2 clinical is intended to assess the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Enrolled patients are stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer. The open-label, multi-center clinical trial is a two-stage design, with pre-determined criteria for continuation after an initial cohort of patients have been treated.

In the Phase 1b trial, carfilzomib demonstrated activity in advanced solid tumors, with partial responses observed in renal cancer and small cell lung cancer patients. A total of 55 patients are currently evaluable for response in the Phase 1b and Phase 2 clinical studies.

Carfilzomib was generally well tolerated. The most common adverse events include fatigue headache, nausea, diarrhea, constipation and anemia. Notably, there were no incidents of Grade 3/4 neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. To date, 65 patients in the Phase 1b and Phase 2 clinical trials have received 154.5 cycles of carfilzomib.

"We are genuinely excited by growing clinical evidence for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib is well tolerated and active across a number of different tumor types in patients with advanced cancers," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "We are committed to expeditiously demonstrating the treatment benefits of carfilzomib in multiple treatment settings. We expect to complete the first stage of our Phase 2 trial in advanced solid tumors and our late-stage clinical studies of carfilzomib in multiple myeloma, and we are actively planning a Phase 3 clinical trial in relapsed multiple
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...NTA, Georgia, November 30 /PRNewswire-FirstCall/ -...-based curriculum for direct support,professionals...ier and the, University of Minnesota,s Research a...d Disability Intensive Course (DIC) on "Cerebral P...ners to use as part of the online,curriculum. It i...
(Date:11/29/2009)... Elastography is an effective, convenient techniqu...tinguish cancerous breast lesions from benign resu... at the annual meeting of the Radiological Society...ields suspicious findings, physicians often use ul..., ultrasound has the potential to result in more b...
(Date:11/29/2009)..., Nov. 29 VIDA Diagnostics, a lead... the advanced analysis of pulmonary diseases, and ...invasive delivery of interventional oncology thera...tive agreement covering joint development and dist...iopsy system. ,, "Veran,s innovative instrumen...
Breaking Medicine Technology:Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 2Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 3Elastography Reduces Unnecessary Breast Biopsies 2Elastography Reduces Unnecessary Breast Biopsies 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 1New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out of Pocket Costs Not Filling Prescriptions 49210 2Brain detects happiness more quickly than sadness 49206 1Brain detects happiness more quickly than sadness 49206 2Sands of Gobi Desert yield new species of nut cracking dinosaur 8871 1Sands of Gobi Desert yield new species of nut cracking dinosaur 8871 2
...Pa., Feb. 24 BioTrends is pleased to announce the...ds(TM): Uloric (R) . Takeda Pharmaceutical Co...roval for Uloric (R) (generic name: febuxostat)... for the chronic management of hyperuricemia assoc...or gout that has been approved in over forty years...
...Pa., Feb. 24 Kensey Nash Corporation (Nasdaq: K...estigational Device Exemption (IDE) application to...udy the use of the Company,s unique biomaterials t... of the knee. The clinical trial will utilize the ...of a proprietary bi-phasic, bioresorbable implant ...
Other Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4
(Date:11/30/2009)... To best serve our patients, their caregi...ith the Institute of Women,s Health of North Ameri...nation. This service is available to all individua...it our website to locate a convenient LOCATION n... (Vocus) November 30, 2009 -- According to...
(Date:11/30/2009)... Smoking is on the rise in the developing...e a hard commitment to stop smoking cigarette, but...(E-Cig) can actually help people quit smoking ciga... a site designated to help heavy smokers cut down ... Los Angeles, CA (PRWEB) Nove...
(Date:11/30/2009)... CLEVELAND, Ohio, November 30 Sim...per of medical simulation systems, in collaboratio...Ocedure Rehearsal Studio(TM),workshop for the firs...Germany. , The Simbionix PROcedure Rehear...tor to enable clinicians to create practice scenar...
(Date:11/30/2009)...ge proportion of patients who undergo abdominal/pe...and unnecessary additional image acquisition resul...rding to a study presented today at the annual mee...(RSNA). , "It is the responsibility of all physi...hat the dosage is as low as reasonably achievable ...
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery...e , Brno, Czech Republic ...ion solution provider, is pleased to announce its ...2009, to be held in Nanjing, China, on November 30...nion-based companies that have established and gro...
Breaking Medicine News(10 mins):Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 3Health News:Stop Smoking Cigarette with Electronic Cigarette (E-Cig), Today You Can Quit Smoking Too 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 3Health News:Unindicated CT series result in unnecessary radiation exposure for patients 2Health News:Unindicated CT series result in unnecessary radiation exposure for patients 3Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2
...chools, education, exercise, public ,children,obes...roximately 50%f California's public schools viol...at least 20 minutes a day for physical education a...duty to provide sufficient exercise to the studen...
...nder fish medicine for asthma patients began here ...cy //. Hundreds of people were seen standing...enamed as fish 'prasadam' or holy offering by Bath...ixed by astrologers, after family members offered ...
...ing lists for patients in Britain, they are forced...hem a fortune //. For example citing an arth...nds of pounds so that he can be cured fast, could ...hritis. The bad part is none of them has been succ...
...ike ultrasound and computed tomography (CT), magne...l be made better by the newly developed multi-moda...y of Illinois at Urbana-Champaign says. Use of...t of speech and hearing science and the Beckman In...
...on BP medication during first trimester of pregnan...n babies - The Food and Drug Administration report...lt University Medical Center. The study, led b...thers who took angiotensin converting enzyme inhib...
...ps told MSPs that charging patients and their rela... // They also voiced their concerns about in... parking because of centralisation of hospital ser...d that without parking charges shoppers would also...
Other Medicine News:Health News:Administration of Fish Drug for Asthma Patients Begins in Andhra 2Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 2Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 3Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 4Health News:Birth Defects Link With ACE Inhibitor Use, FDA Reports 2
MAXITROL Ophthalmic Oinent
...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
Veris Fundus
Sinoscopy Trocar And Cannula
Medicine Products: